PI 3-Kinase p85 alpha [p Tyr199, p Tyr467] Antibody (PSH01-38)

Name: PI 3-Kinase p85 alpha [p Tyr199, p Tyr467] Antibody (PSH01-38)
Brand: Novus Biologicals
SKU: NBP3-32818
Price: 439 USD
Availability: InStock

Novus Biologicals | Catalog # NBP3-32818

Submit a review

Product Documents

Recombinant Monoclonal Antibody

100% Guarantee

Product Specifications
Scientific Data
Applications
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Species Reactivity

Human, Mouse

Applications

Western Blot, Immunocytochemistry/ Immunofluorescence

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # PSH01-38 expressed in HEK293

View all PI 3-Kinase p85 alpha Primary Antibodies »

Product Specifications

Immunogen

Synthetic peptide within human PI 3-Kinase p85 alpha aa 451-500 / 724. (Uniprot: P27986)

Modification

p Tyr 467, p Tyr 199

Localization

Cell-cell junction, cis-Golgi network, cytoplasm, cytosol, membrane, nucleus.

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for PI 3-Kinase p85 alpha [p Tyr199, p Tyr467] Antibody (PSH01-38)

Western Blot: PI 3-Kinase p85 alpha [p Tyr199, p Tyr467] Antibody (PSH01-38) [NBP3-32818]

Western Blot: PI 3-Kinase p85 alpha [p Tyr199, p Tyr467] Antibody (PSH01-38) [NBP3-32818] - Western blot analysis of PI 3-Kinase p85 alpha on different lysates with Rabbit anti-PI 3-Kinase p85 alpha antibody (NBP3-32818) at 1/1,000 dilution.

Lane 1: NIH/3T3 whole cell lysate
Lane 2: NIH/3T3 treated with 1mM sodium orthovanadate for 30 minutes whole cell lysate

Lysates/proteins at 30 ug/Lane.

Predicted band size: 84 kDa
Observed band size: 55/85 kDa

Exposure time: 3 minutes 10 seconds;

4-20% SDS-PAGE gel.

Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (NBP3-32818) at 1/1,000 dilution was used in 5% NFDM/TBST at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1/100,000 dilution was used for 1 hour at room temperature.

Immunocytochemistry/ Immunofluorescence: PI 3-Kinase p85 alpha [p Tyr199, p Tyr467] Antibody (PSH01-38) [NBP3-32818]

Immunocytochemistry/ Immunofluorescence: PI 3-Kinase p85 alpha [p Tyr199, p Tyr467] Antibody (PSH01-38) [NBP3-32818] - Immunocytochemistry analysis of NIH/3T3 cells treated with or without 1mM Sodium orthovanadate for 30 minutes labeling PI 3-Kinase p85 alpha with Rabbit anti-PI 3-Kinase p85 alpha antibody (NBP3-32818) at 1/100 dilution.

Cells were fixed in 4% paraformaldehyde for 20 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 5 minutes at room temperature, then blocked with 1% BSA in 10% negative goat serum for 1 hour at room temperature. Cells were then incubated with Rabbit anti-PI 3-Kinase p85 alpha antibody (NBP3-32818) at 1/100 dilution in 1% BSA in PBST overnight at 4 ℃. Goat Anti-Rabbit IgG H&L (iFluor™ 488) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. Nuclear DNA was labelled in blue with DAPI.

Beta tubulin (red) was stained at 1/100 dilution overnight at +4℃. Goat Anti-Mouse IgG H&L (iFluor™ 594) was used as the secondary antibody at 1/1,000 dilution.

Applications for PI 3-Kinase p85 alpha [p Tyr199, p Tyr467] Antibody (PSH01-38)

Application

Recommended Usage

Immunocytochemistry/ Immunofluorescence

1:100

Western Blot

1:1000

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS (pH7.4), 0.1% BSA and 40% Glycerol

Preservative

0.05% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: PI 3-Kinase p85 alpha

Phosphatidylinositol 3-kinase (PI3K) p85 alpha is a regulatory subunit that heterodimerizes with a catalytic subunit to form a Class IA PI3K enzyme complex, which plays an important role in the immune system (1,2). The P13K pathway is involved in many diverse processes including growth, metabolism, proliferation, and survival (2). PI3Ks are typically activated by cytokine receptors and are responsible for phosphorylation of the 3'-hydroxyl group of PI and its derivatives (3). p85 alpha is one of five regulatory subunit proteins which also includes p55 alpha, p50 alpha, p85 beta, and p55 gamma, and can bind to two of the three catalytic subunits (p110 alpha or p110 delta) (1,2). p85 alpha, p55 alpha, and p50 alpha proteins are all synthesized by the same PIK3R1 gene by alternative splicing (1). Structurally, PI 3-Kinase p85 alpha contains SRC homology 3 (SH3 domain), followed by a Bcr homology (BH) domain flanked by two proline-rich regions, then a N-terminal SH2 domain, an inter-SH2 domain, and C-terminal SH2 domain (1,2). PI 3-Kinase p85 alpha protein consists of 724 amino acids (aa) in length with a theoretical molecular weight of 83.5 kDa (2,4). The primary role for the p85 subunit is interaction with cell surface receptors and acts as an adapter for the stabilization and recruitment of the p110 catalytic subunit to the plasma membrane (1,3). Additionally, p85 has been shown to function in both interleukin-2 receptor (IL2R) and erythropoietin receptor (EpoR) endocytosis (3).

The PI3K pathway functions in a broad range of cellular processes, so it is understandable that pathway dysfunction can lead to an array of diseases and disorders (2,5). Elevated PI3K signaling is a key feature of many cancers (5). PI3K pathway dysregulation has also been implicated in neurological, metabolic, and cardiovascular disorders (5). Furthermore, both overactivation or under-activation of the PI3K delta (p85 alpha subunit + p110 delta subunit) pathway has been shown to cause immunodeficiency and pathologies related to immune system dysfunction (2). Therapeutics to target the PI3K pathway and treat related cancers include PI3K inhibitors and, specifically, isoform-selective inhibitors which have a lot of promise when used as part of a combination therapy (5).

References

1. Okkenhaug, K., & Vanhaesebroeck, B. (2001). New responsibilities for the PI3K regulatory subunit p85 alpha. Science's STKE : signal transduction knowledge environment. https://doi.org/10.1126/stke.2001.65.pe1

2. Nunes-Santos, C. J., Uzel, G., & Rosenzweig, S. D. (2019). PI3K pathway defects leading to immunodeficiency and immune dysregulation. The Journal of allergy and clinical immunology. https://doi.org/10.1016/j.jaci.2019.03.017

3. Chen, P. H., Yao, H., & Huang, L. J. (2017). Cytokine Receptor Endocytosis: New Kinase Activity-Dependent and -Independent Roles of PI3K. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2017.00078

4. Uniprot (P27986)

5. Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017). The PI3K Pathway in Human Disease. Cell. https://doi.org/10.1016/j.cell.2017.07.029

Long Name

PI 3-Kinase p85 alpha

Alternate Names

GRB1, PI 3Kinase p85 alpha, PIK3R1

Gene Symbol

PIK3R1

Additional PI 3-Kinase p85 alpha Products

Product Documents for PI 3-Kinase p85 alpha [p Tyr199, p Tyr467] Antibody (PSH01-38)

Download Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for PI 3-Kinase p85 alpha [p Tyr199, p Tyr467] Antibody (PSH01-38)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.